ストックスクリーナーアプリを入手
7.38
0.27%
0.02
アフターアワーズ：
7.38
前日終値:
$7.36
開ける：
$7.35
24時間の取引高:
139.93K
Relative Volume:
2.11
時価総額：
$54.40M
収益：
$7.00M
当期純損益:
$-56.03M
株価収益率:
-0.9636
EPS:
-7.6589
ネットキャッシュフロー:
$-51.79M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+7.74%
6か月 パフォーマンス:
+71.63%
1年 パフォーマンス:
+79.56%
1日の値動き範囲:
$7.34
$7.395
1週間の範囲:
$7.32
$7.50
52週間の値動き範囲:
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
名前
Kezar Life Sciences Inc
セクター
電話
650-822-5600
住所
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.38 | 54.25M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-17 | ダウングレード | Jefferies | Buy → Hold |
| 2025-10-17 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Wells Fargo | Outperform |
| 2018-07-16 | 開始されました | William Blair | Outperform |
すべてを表示
Kezar Life Sciences Inc (KZR) 最新ニュース
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? - Benzinga
M&A Class Action Firm Investigating Multiple Mergers - National Today
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Working capital per share of Kezar Life Sciences Inc – FWB:2KZ0 - TradingView — Track All Markets
KZR Technical Analysis & ETF Price Forecast - Intellectia AI
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - GuruFocus
Weekly Trades: Will Kezar Life Sciences Inc announce a stock splitInsider Buying & Safe Swing Trade Setups - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Published on: 2026-04-10 03:01:28 - baoquankhu1.vn
Sectors Review: What are Kezar Life Sciences Incs recent SEC filings showing2026 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, CNTA, AFBI, and APLS - Morningstar
Growth Value: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? - Finviz
Pullback Watch: What is the next catalyst for Kezar Life Sciences Inc2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Shareholder Alert: Ademi LLP investigates whether Kezar - GlobeNewswire
Baselake reports 5.3% stake in Kezar Life Sciences (NASDAQ: KZR) - Stock Titan
Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - msn.com
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - Investing.com South Africa
Kezar Life Sciences Announces Major Executive Leadership Changes - TipRanks
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Kezar Life Sciences' Christopher J. Kirk, Marc L. Belsky and Mark Schiller to Depart under Separation Agreements - TradingView — Track All Markets
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
Kezar Life Sciences, Inc. Announces Resignation of Mark Schiller as Chief Operating Office - marketscreener.com
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Trend Recap: What is Kezar Life Sciences Incs market position2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
Jefferies maintains Kezar Life Sciences stock rating on acquisition By Investing.com - Investing.com India
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Cash Deal - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
Jefferies maintains Kezar Life Sciences stock rating on acquisition - Investing.com
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Shareholder Alert: The Ademi Firm investigates whether Kezar Lif - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire
US Market Wrap: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Kezar Life Sciences Inc (KZR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):